Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Otsuka Achieves 2-Digit Growth Driven by Core Products
February 17, 2025
- Darzquro Filed for High-Risk Smoldering MM in Japan: J&J
February 17, 2025
- Nxera Founder Tamura to Bow Out from Board
February 17, 2025
- Kerendia Filed for Chronic Heart Failure in Japan: Bayer
February 17, 2025
- Takeda Files Liquid Formulation of IVIg Therapy in Japan
February 17, 2025
- Restore Vision Launches Clinical Study of Optogenetic Gene Therapy
February 17, 2025
- FDA Approves Izervay’s Wider Label with No Dosing Duration Limit
February 14, 2025
- Susmed to Get 100 Million Yen Milestone after PMS App Trial Start
February 13, 2025
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Meiji Logs Operating Loss in Vaccine Biz on Kostaive Devaluation
February 12, 2025
- Kobayashi Pharma Scraps Medium-Term Biz Plan Due to Beni-Koji Scandal
February 12, 2025
- Cheplapharm Set to Expand LLP Deals to 20 APIs, Sees Opportunities Despite Headwinds
February 12, 2025
- Eisai/Lion to Discontinue Antiplatelet Bufferin in Japan
February 12, 2025
- Sanofi Japan Files Dupixent for Asthma in Children Aged 6-11
February 12, 2025
- Kyowa Kirin Sees Need for Shift of Japan Business: CEO
February 10, 2025
- Japan Ethical Drug Sales Surge 7.3% in December: Crecon
February 10, 2025
- Kisunla Virtually Has No Impact on Leqembi Sales: Eisai
February 10, 2025
- Bain Picks Up Mitsubishi Tanabe for Over 500 Billion Yen
February 10, 2025
- Meiji to Jointly Market Taisho’s Insomnia Med Vornorexant
February 10, 2025
- Bain Strikes Deal to Buy Mitsubishi Tanabe
February 7, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…